Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease

Keyphrases

• Interstitial Lung Disease 100%
• Calcineurin Inhibitors 100%
• Antisynthetase 100%
• Antisynthetase Autoantibodies 66%
• Tacrolimus 50%
• Cyclosporine 50%
• Transfer RNA (tRNA) 33%
• Disease-associated 33%
• Autoantibodies 33%
• First-line Therapy 33%
• Refractory Cases 33%
• Synthetase 33%
• Age of Onset 16%
• Therapeutic Potential 16%
• Rheumatology 16%
• Clinical Response 16%
• Dermatomyositis 16%
• Myositis 16%
• Idiopathic Inflammatory Myopathies 16%
• Medical Records 16%
• Lung Disease 16%
• Anti-Jo-1 16%
• Pulmonary Function Test 16%
• Polymyositis 16%
• Refractory Disease 16%
• PL-12 16%

Medicine and Dentistry

• Interstitial Lung Disease 100%
• Calcineurin Inhibitor 100%
• Autoantibodies 100%
• Cyclosporine 50%
• Tacrolimus 50%
• Myositis 33%
• Onset Age 16%
• Dermatomyositis 16%
• Lung Function Test 16%
• Silo-Filler's Disease 16%
• Polymyositis 16%
• Experimental Rheumatology 16%
• Amino Acid Transfer RNA Ligase 16%
• Histidine Transfer RNA Ligase 16%
• Medical Record 16%
• Diseases 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Interstitial Lung Disease 100%
• Autoantibodies 100%
• Calcineurin Inhibitor 100%
• Ciclosporin 50%
• Tacrolimus 50%
• Myositis 33%
• Lung Disease 16%
• Onset Age 16%
• Dermatomyositis 16%
• Polymyositis 16%
• Amino Acid Transfer RNA Ligase 16%
• Histidine Transfer RNA Ligase 16%
• Diseases 16%